🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Why MEI Pharma Stock Is Plummeting After Hours

Published 24/03/2022, 20:46
© Reuters.  Why MEI Pharma Stock Is Plummeting After Hours
MEIP
-

MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S. Food and Drug Administration.

During the meeting, the FDA informed MEI Pharma that a randomized trial would now be needed to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates, including zandelisib.

MEI Pharma announced the agency 'discouraged a filing based on the Phase 2 TIDAL study data and emphasized that the companies continue efforts with the ongoing, randomized Phase 3 COASTAL study as planned.'

Following FDA recommendations, MEI Pharma said it no longer plans to submit an FDA marketing application based on its single arm Phase 2 TIDAL study.

MEI Pharma is focused on the clinical development of novel therapies for cancer. Zandelisib is an investigational cancer treatment being developed as an oral, once-daily, treatment for patients with B-cell malignancies.

See Also: Why Co-Diagnostics Stock Is Trading Higher After Hours

MEIP 52-Week Range: $1.68 - $3.91

The stock was down 48.1% in after hours, hovering around 94 cents at press time.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.